Document:

EX-10.3

 Exhibit 10.3 

DEED OF IRREVOCABLE UNDERTAKING 
  

	To:	 Xeris Pharmaceuticals, Inc. (“Xeris”) 

180 N. LaSalle Street, Suite 1600, 

Chicago, IL 60601 
 United States
of America 
 Xeris Biopharma Holdings, Inc. (“Holdco”) 

180 N. LaSalle Street, Suite 1600, 

Chicago, IL 60601 
 United States
of America 
 24 May 2021 
 Dear Sirs 

PROPOSED ACQUISITION OF STRONGBRIDGE BIOPHARMA PLC BY HOLDCO, AN AFFILIATED COMPANY OF XERIS PHARMACEUTICALS, INC. 

We, HealthCap VI, L.P. (hereinafter “we”, “us”, and “our”), refer to the proposed acquisition of Strongbridge Biopharma plc (the
“Company”) by Holdco, a newly incorporated company and affiliate of Xeris. Under the proposed transaction, Holdco will offer to acquire the entire issued and to be issued ordinary share capital of the Company pursuant to a Scheme or
Takeover Offer (as defined in paragraph 6) (the “Proposed Transaction”) substantially on the terms and subject to the conditions set out in the Rule 2.5 announcement to be issued on today’s date (the “Rule 2.5
Announcement”) (attached at Schedule 2 to this Undertaking). 
 We understand that the Proposed Transaction is currently proposed to be implemented
by way of the Scheme and that it is proposed that the terms of the Scheme will be contained in a document prepared and issued by the Company (and addressed, inter alia, to the shareholders of the Company) that would be a scheme circular for the
purpose of the Rules and the Act (the “Scheme Document”). 
 This Undertaking sets out the terms and conditions on which we will vote (or
procure a vote) in favour of the Proposed Transaction and the Scheme in respect of the Subject Shares, or if applicable, accept the Takeover Offer (as defined in paragraph 6). 

Capitalised terms used in this Undertaking shall have the meaning given to such terms in paragraph 12 below unless otherwise defined. 

 

	1.	 Shareholdings 

Subject to the announcement of the Proposed Transaction pursuant to the Rule 2.5 Announcement, we hereby represent and warrant to you that: 

 

	1.1	 set out in part 1 of Schedule 1 are true, complete and accurate details of the ordinary shares of $0.01 each in
the share capital of the Company of which we are the registered and/or beneficial owner (or are otherwise able to control the exercise of all rights attaching to such shares) and we confirm that we own these free of any encumbrances or third party
rights of any kind (the “Company Shares”); 

  

	1.2	 set out in part 2 of Schedule 1 are true, complete and accurate details of all options, warrants or other
rights to subscribe for, purchase, convert into, exchange or exercise for or otherwise acquire or call for delivery of any shares of the Company, including, without limitation, the Company Options, (together with any further such options, warrants
and other such rights which we, or the Nominee, may become entitled to and/or receive at any time after the date of this Undertaking (the “Convertible Shares”); 

  
 1 

	1.3	 other than as set out in Schedule 1 and save for any rights provided for in the articles of association of the
Company and/or pursuant to company law in favour of the holders of Company shares generally, we do not have any interest (as defined in the Rules) in any shares of the Company or any right to subscribe for, purchase, convert into, exchange or
exercise for or otherwise acquire or call for delivery of any such shares; 

  

	1.4	 we have all necessary power and authority to direct the actions of any nominee or custodian who holds legal
title to the Subject Shares (as defined in paragraph 2.1.1 below) on our behalf (the “Nominee”) to enable us to comply with the Obligations; and 

 

	1.5	 we have full power and authority, and the right (free from any legal or other restrictions), and will at all
times continue to have all relevant power and authority and the right, to enter into and perform the Obligations. 

  

	2.	 Dealings and undertakings 

 

	2.1	 Subject to the announcement of the Proposed Transaction pursuant to the Rule 2.5 Announcement on today’s
date, we hereby unconditionally and irrevocably agree and undertake to you that (other than in connection with the Proposed Transaction) before this Undertaking lapses in accordance with paragraph 8, we shall not, and shall procure that, in respect
of the Subject Shares (as defined in paragraph 2.1.1 below) only, the Nominee on our behalf shall, not directly or indirectly: 

  

	 	2.1.1	 sell, transfer, assign, tender in any tender or exchange offer, dispose of, charge, pledge or otherwise
encumber or grant any option or award or other right over or otherwise deal with any of the Company Shares, Convertible Shares or Further Company Shares (together, the “Subject Shares”) or any interest in any of them (whether
conditionally or unconditionally), except as set forth in the Transaction Agreement; 

  

	 	2.1.2	 vote in favour of any resolution to approve (i) an acquisition of any shares in the Company by any person
other than Holdco (or any member of the Xeris Group, or (ii) any other transaction which is proposed by any person other than Holdco (or any member of the Xeris Group) which relates to the shares of the Company or which could otherwise hinder
or impede the implementation of the Scheme; 

  

	 	2.1.3	 withdraw the votes in favour of the Scheme referred to in paragraph 3 or the acceptance(s) in the case of a
Takeover Offer referred to in paragraph 6 in respect of all or any of the Subject Shares notwithstanding that we may have become entitled to effect such withdrawal by virtue of the Rules or otherwise by the terms of the Proposed Transaction, and
shall procure that any vote by us in favour of the Scheme (or acceptance in the case of a Takeover Offer) in respect of the Subject Shares is not withdrawn; 

  

	 	2.1.4	 deposit any Subject Shares into a voting trust or enter into a voting agreement or arrangement or grant any
proxy or power of attorney with respect thereto that is inconsistent with this Undertaking; 

  

	 	2.1.5	 in our capacity as shareholder of the Company, without the consent of Xeris, take any step, including voting
the Subject Shares, requisitioning, or joining in requisitioning of, any general or class meeting of the Company, or take any other action, that would or might reasonably be expected to restrict or impede the Scheme becoming effective or, as the
case may be, the Takeover Offer becoming unconditional; 

  

	 	2.1.6	 accept or give any undertaking to accept any offer made or proposed to be made in respect of any shares in the
Company (by whatever means the same is to be implemented) by any person other than Holdco (or any member of the Xeris Group); or 

  

	 	2.1.7	 enter into any agreement or arrangement (whether or not legally binding) with any person, whether conditionally
or unconditionally, or give any public indication of intent which would or might reasonably be expected to restrict the acquisition of the Subject Shares by Xeris or Holdco under the Proposed Transaction. 

 

	2.2	 We further undertake to you that we shall not, until this Undertaking lapses in accordance with paragraph 8,
acquire any interests (as defined in the Rules) or otherwise deal or undertake any dealing (also as defined in the Rules) in any Relevant Securities of the Company (including, for the avoidance of doubt, the exercising, exchange or conversion of any
Convertible Shares), except as set forth in the Transaction Agreement and excluding any Relevant Securities acquired pursuant to the exercise of the Company Options. 

  
 2 

	3.	 Undertaking to vote in favour of the Scheme 

Unless and until this Undertaking ceases to have any effect in accordance with paragraph 8, we hereby irrevocably and unconditionally agree and
undertake to you that: 
  

	3.1	 We shall (unless Xeris otherwise requests in writing in advance) exercise, or (as appropriate) procure the
exercise of, all voting rights attaching to the Subject Shares to vote in favour of all resolutions (including a Relevant Resolution) to approve the Proposed Transaction, the Scheme, and any related matters proposed at any general or class meeting
of the Company in connection with the Scheme (“EGM”) and any meeting or class meeting of the Company convened pursuant to section 450 of the Act to approve the Scheme (a “Scheme Meeting”) or at any adjournment or
postponement of any such meeting (all such resolutions collectively, the “Scheme Resolutions”); 

  

	3.2	 We shall execute, or (as appropriate) procure the execution of, any forms of proxy in respect of the Subject
Shares required by Xeris validly appointing the Chairman of the meeting or any person nominated by Xeris to attend and vote at any EGM and/or Scheme Meeting (or any adjournment or postponement thereof) in respect of the Scheme Resolutions, and shall
ensure that any such executed forms of proxy are received by the Company’s registrars not later than 5:00 p.m. (Irish Time) on the tenth Business Day after the Company sends the Scheme Document to the Company’s shareholders (or, in respect
of any Further Company Shares, within five days of acquiring an interest in such shares, if later); 

  

	3.3	 We shall not revoke (or seek to cause the revocation of) the terms of any proxy submitted in accordance with
paragraph 3.2, either in writing or by attendance at any EGM or Scheme Meeting (or any adjournment or postponement thereof) or otherwise; and 

  

	3.4	 We shall not exercise any voting rights attaching to the Subject Shares to vote in favour of any scheme of
arrangement that is proposed in competition with the Proposed Transaction. 

  

	3.5	 A “Relevant Resolution” means: 

 

	 	3.5.1	 any Scheme Resolution; 

 

	 	3.5.2	 any other resolution (whether or not amended) proposed at a general or class meeting of the Company, or at an
adjourned meeting, the passing of which is necessary to implement the Scheme; and 

  

	 	3.5.3	 a resolution to adjourn a general or class meeting of the Company whose business includes the consideration of
any Scheme Resolution and which is recommended by the board of directors of the Company. 

  

	4.	 Documentation 

 

	4.1	 We consent to: 

  

	 	4.1.1	 this Undertaking being disclosed to the Panel; 

 

	 	4.1.2	 the inclusion of references to us and particulars of this Undertaking and our holdings of relevant securities
of the Company being included in the Rule 2.5 Announcement (attached at Schedule 2 hereto), and any Scheme Document, and any other announcement made, or document issued, by or on behalf of the Company and/or Xeris in connection with the Proposed
Transaction; and 

  

	 	4.1.3	 this Undertaking being available for inspection as required by the Rules. 

  
 3 

	4.2	 We shall promptly give you all such information with respect to our holding of Subject Shares and any
assistance as you may reasonably require for the preparation of the Rule 2.5 Announcement, any Scheme Document and any other announcement to be made, or document to be issued, by or on behalf of Xeris, Holdco or the Company in connection with the
Proposed Transaction in order to comply with the requirements of the Rules, the Panel, or any other applicable legal or regulatory requirement. 

  

	5.	 Confidentiality 

We shall keep the possibility, terms and conditions of the Proposed Transaction and the existence of this Undertaking confidential until the
Rule 2.5 Announcement is released, provided that we may disclose the same to the Company, its advisers and our advisers (and, in the case of our advisers we shall procure that they observe confidentiality in the same terms). The Obligations in this
paragraph 5 shall survive termination or lapse of this Undertaking. 
  

	6.	 Implementation by way of takeover offer 

 

	6.1	 We acknowledge that Xeris shall have (in accordance with the terms of the Transaction Agreement) the right and
may elect at any time (with the consent of the Panel (if required) and whether or not the Scheme Document has then been despatched) to implement the Proposed Transaction by way of a takeover offer (the “Takeover Offer”), as opposed
to by way of a Scheme, provided that: 

  

	 	6.1.1	 Xeris has made that election in accordance with the terms of the Transaction Agreement; and

  

	 	6.1.2	 such Takeover Offer is made on terms at least as favourable in the aggregate as the terms of the Scheme (except
in relation to the acceptance condition which will be set at 80% of the shares to which such Takeover Offer relates or such lesser percentage as Xeris may, with the consent of the Panel (if required), decide). 

 

	6.2	 If such a Takeover Offer is made by Holdco (or any other member of the Xeris Group), we undertake and warrant
that, notwithstanding any other provision of this Undertaking, any undertakings, agreements, warranties, appointments, consents and waivers in this Undertaking shall apply mutatis mutandis to such Takeover Offer and, in particular, we undertake to
accept, or procure the acceptance of, such Takeover Offer, in respect of the Subject Shares. We further undertake, if so required by Xeris, to promptly execute or procure the execution of all such other documents as may be necessary for the purpose
of giving Xeris the full benefit of the undertakings herein with respect to such Takeover Offer. 

  

	6.3	 References in this Undertaking to: 

 

	 	6.3.1	 the Scheme becoming effective shall be read as references to the Takeover Offer becoming or being declared
unconditional in all respects; 

  

	 	6.3.2	 the Scheme lapsing or being withdrawn shall be read as references to the lapse or withdrawal of the Takeover
Offer; and 

  

	 	6.3.3	 the Scheme Document shall be read as references to the Offer Document. 

 

	7.	 Time of the essence 

Any time, date or period mentioned in this Undertaking may be extended by mutual agreement but as regards any time, date or period originally
fixed or as extended, time shall be of the essence. 
  

	8.	 Lapse of undertaking 

 

	8.1	 Notwithstanding any other provision of this Undertaking, this Undertaking (and all of our Obligations) shall
lapse and cease to have any effect on and from the earliest of the following occurrences: 

  

	 	8.1.1	 the Rule 2.5 Announcement is not released on 24 May 2021; 

  
 4 

	 	8.1.2	 Holdco publicly announces that it does not intend to make or proceed with the Acquisition (as defined in the
Transaction Agreement); 

  

	 	8.1.3	 the Acquisition (as defined in the Transaction Agreement) lapses or is withdrawn (which, for the avoidance of
doubt, will not be deemed to have occurred only by reason of Xeris electing to switch from a Scheme to a Takeover Offer in accordance with paragraph 6); 

  

	 	8.1.4	 the Transaction Agreement is validly terminated in accordance with its terms; 

 

	 	8.1.5	 the Scheme becomes effective; 

 

	 	8.1.1	 a third party announces in accordance with the Rules a firm intention to make an offer (whether recommended or
not) to acquire the entire issued and to be issued share capital of the Company not already owned by such third party (a “Third Party Offer”) provided that the terms of any such Third Party Offer must provide for a consideration per
share which is not less than 105% of the value of the consideration offered under the Scheme (including for the avoidance of doubt the value of the CVR Consideration), as at the date on which the Third Party Offer is announced; or

  

	 	8.1.2	 31 December 2021. 

 

	8.2	 If this Undertaking lapses, neither Xeris nor HoldCo shall have any claim against us under this Undertaking
other than in respect of a prior breach by us of this Undertaking. 

  

	9.	 Governing law 

This Undertaking and any suit, action or proceedings that may arise out of or in connection with it shall be governed by and construed in
accordance with the laws of Ireland and we agree that the courts of Ireland are to have exclusive jurisdiction to hear and determine any suit, action or proceedings that may arise out of or in connection with this Undertaking and, for such purposes,
we irrevocably submit to the jurisdiction of such courts. 
  

	10.	 Specific performance 

Without prejudice to any other rights or remedies which you may have, we acknowledge and agree that damages may not be an adequate remedy for
any breach by us of any of the Obligations and Xeris and/or Holdco shall be entitled to the remedies of injunction, specific performance and other equitable relief for any threatened or actual breach of any of the Obligations and no proof of special
damages shall be necessary for the enforcement by you of your rights. 
  

	11.	 Severability 

The covenants and undertakings contained in this Agreement and each part of them are entirely severable and separately enforceable so that each
covenant and undertaking and each part of them shall be deemed to be a separate covenant and undertaking. 
  

	12.	 Interpretation 

 

	12.1	 In this Undertaking, the following words and expressions shall have the meaning set opposite them:

 “Act” means the Companies Act 2014, all enactments which are to be read as one with, or construed or
read together with the Companies Act 2014 and every statutory modification and re-enactment thereof for the time being in force; 

“Business Day” means any day, other than a Saturday, Sunday or public holiday in Dublin or London; 

“Company Options” means any options or awards outstanding under any Company Share Plans; 

“Company Share Plans” shall have the meaning given to that term in the Transaction Agreement; 

  
 5 

 “CVR Consideration” shall have the meaning given to that term in the
Transaction Agreement; 
 “Further Company Shares” means (i) any further shares in the share capital of the Company in
respect of which we acquire an interest and in respect of which we are entitled to exercise, or direct the manner of exercise of, the voting of such shares and (ii) any other shares in the share capital of the Company that are attributable to
or derived from any such further shares mentioned in limb (i) of this definition; 
 “interest” and
“interested” have the meanings given to those terms in the Rules; 
 “Obligations” means our undertakings,
agreements, warranties, appointments, consents and waivers set out in this Undertaking; 
 “Panel” means the Irish Takeover
Panel; 
 “Relevant Securities” has the meaning given to that term in the Rules; 

“Rules” means The Irish Takeover Panel Act 1997, Takeover Rules 2013; 

“Scheme” means the proposed scheme of arrangement under Chapter 1 of Part 9 of the Act to effect the Proposed Transaction, on
the terms (including the conditions) and for the consideration set out in the Rule 2.5 Announcement and on such other terms and in such form not being inconsistent therewith as Xeris and the Company mutually agree in writing, including any revision
hereof as may be so agreed between Xeris and the Company; 
 “Subsidiary” means in relation to any person, any corporation,
partnership, association, trust or other form of legal entity of which such person directly or indirectly owns securities or other equity interests representing more than 50% of the aggregate voting power; 

“Transaction Agreement” means the transaction agreement dated on or around the date of this Undertaking between, amongst
others, the Company, Holdco and Xeris; 
 “Undertaking” means this deed of irrevocable undertaking; and 

“Xeris Group”, means Xeris, Holdco, and each of their respective affiliates. 

 

	12.2	 Unless otherwise defined, capitalised terms shall have the meaning given to them by the Rules.

  

	13.	 Assignment 

Xeris may not assign any of its rights and obligations under this Undertaking without our prior written consent other than to Holdco or a body
corporate under the same ultimate ownership as Xeris and then only if such body corporate is the “offeror” for the purposes of any Takeover Offer, in the event of such an assignment, any reference to “Xeris” shall be construed as
a reference to such body corporate. 
  

	14.	 Power of Attorney 

 

	14.1	 In order to secure the performance of the Obligations, for so long as this Undertaking has not lapsed in
accordance with paragraph 8, we hereby irrevocably appoint individually or collectively each and every one of the directors of Holdco (each, an “Attorney”) to be our attorney in our name and on our behalf to execute any form or
forms of acceptance and/or such other documents and do such other acts or things (if any) as may be reasonably necessary to accept and/or vote in favour of the Scheme and/or to otherwise satisfy the Obligations in respect of our Subject Shares.

  

	14.2	 The power of attorney granted under this paragraph 14 shall at any time take effect as if it had individually
named the persons who are at that time directors of Holdco. 

  

	14.3	 Any action authorised under this power of attorney may be taken by any Attorney acting alone.

  
 6 

	14.4	 We hereby irrevocably undertake to ratify any such act committed in exercise of this power, if called upon to
do so. We also acknowledge that this power of attorney is irrevocable until this Undertaking lapses in accordance with its terms. 

  

	15.	 Acknowledgments and undertaking 

 

	15.1	 We hereby accept and acknowledge that, subject to paragraph 8, the Obligations assumed pursuant to this
Undertaking are irrevocable. 

  

	15.2	 We hereby accept and acknowledge that we have not entered into this Undertaking relying on any statement or
representation, whether or not made by Xeris or Holdco (or any of their respective directors, officers, employees or agents) or any other person and that nothing in this Undertaking obliges Xeris or Holdco to announce or proceed with the Scheme or
despatch the Scheme Document in the event that it is not required to do so by the Rules. 

  

	15.3	 We undertake to give such directions to the Nominee to take such acts and do such things as are necessary to
give Xeris and Holdco the full benefit of this Undertaking. References in this Undertaking to Obligations on our part shall be construed to include obligations, wherever relevant, to procure that equivalent actions be taken by the Nominee.

  
 7 

 Schedule 1 

Part 1 - Company Share Details 
  

									
	 Class
	  	Number	 	  	 Registered Holder
	  	 Ultimate Beneficial Owner

	 Ordinary
	  	 	3,268,004	 	  	Cede & Co	  	HealthCap VI, L.P.

 Part 2 - Convertible Shares Details 

 

									
	 Date of grant
	  	Number of shares
under option/
award	  	Exercise Period	  	Exercise price	 
	 28 December 2016
	  	Warrants: 400,000	  	28 June 2022	  	$	2.50	 
	 18 May 2021
	  	RSUs: 40,000	  	18 May 2022	  	 	n/a	 
	 16 October 2015
	  	Options: 9,918	  	16 October 2025	  	$	17.55	 
	 16 October 2015
	  	Options: 25,000	  	16 October 2025	  	$	17.55	 
	 12 May 2026
	  	Options: 40,000	  	12 May 2026	  	$	5.50	 
	 11 May 2017
	  	Options: 40,000	  	11 May 2027	  	$	4.40	 
	 15 May 2018
	  	Options: 40,000	  	15 May 2028	  	$	7.75	 

  
 8 

 Schedule 2 

Rule 2.5 Announcement 

  
 9 

 In witness whereof this Deed has been duly executed and delivered as a deed poll on the date shown at the
beginning of this document 
  

			
	 EXECUTED AND DELIVERED by
 HealthCap VI
GP SA as a deed
 on behalf of
  

HEALTHCAP VI, L.P.
	  	
		  	  
 Signature

	Witness to Signature	  	
		  	
	  
 Witness
	  	
		  	
	  
 Print Name of Witness
	  	
		  	
	  
 Print Address of Witness
	  	
		  	
	  
 Occupation of Witness
	  	

  
 10EX-10.4

 Exhibit 10.4 

CONSENT UNDER AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT 

This Consent (“Consent”) under the Loan Agreement (as defined below) is entered into as of May 24, 2021 (the
“Consent Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such
capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation
with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and XERIS PHARMACEUTICALS, INC., a Delaware
corporation with offices located at 180 North LaSalle Street, Suite 1600, Chicago, IL 60601 (“Borrower”). 
 WHEREAS,
Collateral Agent, Borrower and Lenders have entered into that certain Amended and Restated Loan and Security Agreement dated as of September 10, 2019 (as amended, supplemented or otherwise modified from time to time, including by that certain
First Amendment to Amended and Restated Loan and Security Agreement dated as of April 21, 2020, that certain Second Amendment to Amended and Restated Loan and Security Agreement dated as of June 30, 2020, that certain Third Amendment to
Amended and Restated Loan and Security Agreement dated as of August 5, 2020, that certain Fourth Amendment to Amended and Restated Loan and Security Agreement dated as of October 23, 2020, and that certain Fifth Amendment to Amended and
Restated Loan and Security Agreement dated as of May 3, 2021, collectively, the “Loan Agreement”) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; 

WHEREAS, Borrower desires to enter into (a) that certain Transaction Agreement to be dated as of May 24, 2021 by and among Borrower,
Strongbridge Biopharma plc, a public limited company incorporated in Ireland with registered number 562659 (“Target”), Xeris Biopharma Holdings, Inc., a Delaware corporation and a Wholly-Owned Subsidiary of Borrower (“Xeris
Holdco”), and Wells MergerSub, Inc., a Delaware corporation and a Wholly-Owned Subsidiary of Borrower (“Xeris Merger Sub”) and pursuant to which, among other things, Borrower will cause Xeris Holdco to become the parent of
Borrower and Xeris Holdco will acquire Target and its Subsidiaries (such Transaction Agreement, together with all exhibits, appendices, including Appendix III referenced therein, and schedules attached thereto, in the form attached hereto as
Exhibit A and as the same may be amended to the extent permitted by Section 2(b) hereof only, the “Transaction Agreement”) and (b) that certain Expenses Reimbursement Agreement to be dated as of May 24, 2021 by
and between Borrower and Target and pursuant to which Borrower and Target have agreed to certain reimbursement obligations related to the transactions contemplated by the Transaction Agreement (such Expenses Reimbursement Agreement, together with
all exhibits, appendices and schedules attached thereto, in the form attached hereto as Exhibit B and as the same may be amended to the extent permitted by Section 2(b) hereof only, the “Expenses Reimbursement
Agreement”, together with the Transaction Agreement, the “Transaction Documents”). 
 WHEREAS, Section 7.3 of
the Loan Agreement requires Borrower to obtain the consent of the Required Lenders to enter into the Transaction Documents and consummate the transactions contemplated thereby and Borrower has asked Collateral Agent and Required Lenders to provide
such consent; and 
 WHEREAS, Collateral Agent and Required Lenders have agreed to provide consent to Borrower entering into the Transaction
Documents and consummating the transactions contemplated thereby, subject to, and in accordance with, the terms and conditions set forth herein, and in reliance upon the representations and warranties set forth herein. 

NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the
receipt and adequacy of which are hereby acknowledged, Borrower, Collateral Agent and Required Lenders hereby agree as follows: 
  

	 	1.	 Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the
Loan Agreement. 

  
 1 

	 	2.	 Consent. Collateral Agent and Required Lenders hereby consent to Borrower’s execution, delivery and
performance of the Transaction Documents in the forms attached hereto as Exhibit A and Exhibit B and consummation of the transactions contemplated thereby. Any amendment to the Transaction Documents, including any exhibit or schedule
thereto, or waiver of any condition contained therein, that is adverse to Borrower or Lenders in any material respect, or could reasonably be expected to be adverse to Borrower or Lenders in any material respect, shall require the prior written
approval of Required Lenders. 

  

	 	3.	 Limitation of Consent. 

 

	 	a.	 Except for the consents set forth in Section 2 above, Collateral Agent and Required Lenders are not
consenting to, any other transaction or action or inaction in violation of the Loan Agreement or any other Loan Document, whether in connection with the Merger (as defined in the Transaction Agreement) or otherwise. 

 

	 	b.	 The consents set forth in Section 2 above are effective for the purposes set forth herein and shall be
limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document including, without limitation, a waiver of any default or Event of Default
under the Loan Agreement resulting from Borrower’s failure to consummate the transactions contemplated by the Transaction Documents or the breach or fulfilment of any of Borrower’s obligations under the Transaction Documents, or
(b) otherwise prejudice any right or remedy which Lenders may now have or may have in the future under or in connection with any Loan Document. 

  

	 	c.	 This Consent shall be construed in connection with and as part of the Loan Documents and all terms, conditions,
representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect. 

 

	 	4.	 To induce Collateral Agent and Required Lenders to enter into this Consent, Borrower hereby represents,
warrants and covenants to Collateral Agent and Required Lenders as follows: 

  

	 	a.	 Immediately after giving effect to this Consent, (i) the representations and warranties contained in the
Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date) and
(ii) no Event of Default has occurred and is continuing; 

  

	 	b.	 Borrower has the power and due authority to execute and deliver this Consent and to perform its obligations
under the Loan Agreement, as amended by this Consent; 

  

	 	c.	 The organizational documents of Borrower delivered to Collateral Agent in connection with entry into the Loan
Agreement on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of borrower to Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full
force and effect; 

  

	 	d.	 The execution and delivery by Borrower of this Consent and the performance by Borrower of its obligations under
the Loan Agreement, as amended by this Consent, have been duly authorized; 

  

	 	e.	 The execution and delivery by Borrower of this Consent and the performance by Borrower of its obligations under
the Loan Agreement, as amended by this Consent, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material
order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower; 

  
 2 

	 	f.	 The execution and delivery by Borrower of this Consent and the performance by Borrower of its obligations under
the Loan Agreement, as amended by this Consent, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any Governmental Authority binding on Borrower, except
as already has been obtained or made; and 

  

	 	g.	 This Consent has been duly executed and delivered by Borrower and is the binding obligation of Borrower,
enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application relating to or affecting
creditors’ rights and general equitable principles. 

  

	 	5.	 Covenants. Borrower agrees that immediately prior to the Merger except as otherwise noted below, Borrower shall
enter into an amendment to the Loan Agreement and such other Loan Documents with Collateral Agent and Lenders, in each case in form and substance reasonably satisfactory to Collateral Agent and Lenders (the “Amendment”); provided,
that Collateral Agent and Lenders agree that any new covenants or events of default shall be limited to what is described in this Section 5, pursuant to which (a) Section 7.3 of the Loan Agreement and any other provisions of the Loan
Agreement are updated to reflect the terms of this Section 5; (b) each of Xeris Holdco, Xeris Merger Sub, the Target and its Subsidiaries becomes a co-Borrower or guarantor of the Obligations and such
Person grants and pledges to Collateral Agent, for the ratable benefit of Lenders, a perfected security interest in and to the assets, including Intellectual Property, of such Person within sixty (60) days of the effectiveness of the Amendment,
(c) a new financial covenant is added providing that the net cash of Target and its Subsidiaries (net of all acquisition-related expenses and the repayment of the Indebtedness for borrowed money of the Target and its Subsidiaries) as of the day
immediately following the Merger is greater than $0, and (d) each of the defined terms Revenue Milestone A, Revenue Milestone B and Revenue Milestone C is amended to include (i) consolidated revenues of the Target and its subsidiaries and
(ii) an additional requirement that as of the same trailing six-month basis noted in such milestones, revenue from Gvoke® and Ogluo® is not less than $17,280,000 during such six-month period in the case of Revenue Milestone A and not less than $15,552,000 during such six-month period in the case of each of Revenue Milestone B and Revenue Milestone C (for clarity, the trailing six-month revenue milestone amounts of $19,200,000, $23,100,000
and $26,600,000 will not change). Borrower further agrees that (i) any Indebtedness for borrowed money of the Target and any of its Subsidiaries shall be paid in full concurrently with the Merger, and immediately following the Merger, Target
and its Subsidiaries shall not have any Indebtedness or Liens except to the extent permitted by the Loan Agreement, and (ii) Borrower shall not at any time prior to the Merger (A) Transfer to, license to or permit Xeris Holdco or Xeris
Merger Sub to hold any Intellectual Property and (B) Transfer to or permit Xeris Holdco or Xeris Merger Sub to hold any other assets having an aggregate value in excess of Ten Thousand Dollars ($10,000.00). 

 

	 	6.	 Except as expressly set forth herein, the Loan Agreement and the other Loan Documents shall continue in full
force and effect without alteration or amendment. This Consent and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. 

 

	 	7.	 Release by Borrower. 

 

	 	a.	 FOR GOOD AND VALUABLE CONSIDERATION, Borrower hereby forever relieves, releases, and discharges
Collateral Agent and each Lender and their respective present or former employees, officers, directors, agents, representatives, attorneys, and each of them, from any and all claims, debts, liabilities, demands, obligations, promises, acts,
agreements, costs and expenses, actions and causes of action, of every type, kind, nature, description or character whatsoever, whether known or unknown, suspected or unsuspected, absolute or contingent, arising out of or in any manner whatsoever
connected with or related to facts, circumstances, issues, controversies or claims existing or arising from the beginning of time through and including the date of execution of this Amendment solely to the extent such claims arise out of or are in
any manner whatsoever connected with or related to the Loan Documents, the Recitals hereto, any instruments, agreements or documents executed in connection with any of the foregoing or the origination, negotiation, administration, servicing and/or
enforcement of any of the foregoing (collectively “Released Claims”). 

  
 3 

	 	b.	 In furtherance of this release, Borrower expressly acknowledges and waives the provisions of the following and
any similar provision under the laws of any state: 

 “A general release does not extend to claims which the creditor
does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” 

 

	 	c.	 By entering into this release, Borrower recognizes that no facts or representations are ever absolutely certain
and it may hereafter discover facts in addition to or different from those which it presently knows or believes to be true, but that it is the intention of Borrower hereby to fully, finally and forever settle and release all matters, disputes and
differences, known or unknown, suspected or unsuspected in relation to the Released Claims; accordingly, if Borrower should subsequently discover that any fact that it relied upon in entering into this release was untrue, or that any understanding
of the facts was incorrect, Borrower shall not be entitled to set aside this release by reason thereof, regardless of any claim of mistake of fact or law or any other circumstances whatsoever. Borrower acknowledges that it is not relying upon and
has not relied upon any representation or statement made by Bank with respect to the facts underlying this release or with regard to any of such party’s rights or asserted rights. 

 

	 	d.	 This release may be pleaded as a full and complete defense and/or as a cross-complaint or counterclaim against
any action, suit, or other proceeding that may be instituted, prosecuted or attempted in breach of this release. Borrower acknowledges that the release contained herein constitutes a material inducement to Collateral Agent and Lenders to enter into
this Amendment, and that Collateral Agent and Lenders would not have done so but for Collateral Agent’s and Lenders’ expectation that such release is valid and enforceable in all events. 

 

	 	8.	 This Consent shall be deemed effective as of the Consent Date upon the due execution and delivery to Collateral
Agent of this Consent by each party hereto. 

  

	 	9.	 Borrower, Lenders and Collateral Agent agree that this Consent shall be a Loan Document. 

 

	 	10.	 This Consent may be executed in any number of counterparts, each of which shall be deemed an original, and all
of which, taken together, shall constitute one and the same instrument. Delivery by electronic transmission (e.g. “.pdf”) of an executed counterpart of this Amendment shall be effective as a manually executed counterpart signature thereof.

  

	 	11.	 This Consent and the rights and obligations of the parties hereto shall be governed by and construed in
accordance with the laws of the State of New York. 

 [Balance of Page Intentionally Left Blank]

  
 4 

 IN WITNESS WHEREOF, the parties hereto have caused this Consent under the Loan
Agreement to be executed as of the date first set forth above. 
  

			
	BORROWER:
	
	XERIS PHARMACEUTICALS, INC.
		
	By	 	 /s/ Barry M. Deutsch

	Name:	 	Barry M. Deutsch
	Title:	 	Chief Financial Officer

  

			
	COLLATERAL AGENT AND LENDER:
	
	OXFORD FINANCE LLC
		
	By	 	 /s/ Colette H. Featherly

	Name:	 	Colette H. Featherly
	Title:	 	Senior Vice President

  

			
	LENDER:
	
	SILICON VALLEY BANK
		
	By	 	 /s/ Kevin Fleischman

	Name:	 	Kevin Fleischman
	Title:	 	Director

 Exhibit A 

TRANSACTION AGREEMENT 

Please see attached. 

 Exhibit B 

EXPENSES REIMBURSEMENT AGREEMENT 

Please see attached.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]